Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often misleading users about FDA approval. Researchers identified over 70 websites with vague safety disclosures.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, and obesity drugs.